(3S)-4-amino-3-hydroxy-6-methylheptanoic acid | 27512-69-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (3S)-4-amino-3-hydroxy-6-methylheptanoic acid
• CAS: 27512-69-2；49642-07-1；49642-11-7；49642-12-8；49642-13-9；62447-91-0；136781-58-3
• 化学式: C₈H₁₇NO₃
• 分子量: 175.228
• InChiKey: DFVFTMTWCUHJBL-MLWJPKLSSA-N

物化性质

• 熔点：
  209 °C
• 比旋光度：
  D15 -20° (c = 0.64 in water)
• 沸点：
  306.53°C (rough estimate)
• 密度：
  1.1233 (rough estimate)
• 溶解度：
  0.5MHCl：50 mg/mL，澄清，淡黄色

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  83.6
• 氢给体数：
  3
• 氢受体数：
  4

制备方法与用途

生物活性

Statine 是一种罕见的氨基酸，在胃蛋白酶抑制剂（pepstatin）的序列中出现了两次。胃蛋白酶抑制剂是一种对胃蛋白酶和其他酸性蛋白酶具有抑制作用的蛋白酶抑制剂。

体外研究

Statine 是一种不常见的氨基酸，出现在胃蛋白酶抑制剂（pepstatin）的序列中两次。胃蛋白酶抑制剂对胃蛋白酶及其他酸性蛋白酶有抑制效果。此外，Statine 还是之前提出的 pepsin 及其他酸性蛋白酶催化过渡态的一种模拟物。

文献信息

• US4397786A
  申请人：——

  公开号：US4397786A

  公开（公告）日：1983-08-09
• US4876343A
  申请人：——

  公开号：US4876343A

  公开（公告）日：1989-10-24
• US5061808A
  申请人：——

  公开号：US5061808A

  公开（公告）日：1991-10-29
• [EN] DIAGNOSTICS AND METHODS FOR TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSIS AND HEPATIC STEATOHEPATITIS, AND PREVENTION OF COMPLICATIONS THEREOF<br/>[FR] DIAGNOSTICS ET MÉTHODES DE TRAITEMENT DE LA STÉATOSE HÉPATIQUE NON ALCOOLIQUE ET DE LA STÉATOHÉPATITE NON ALCOOLIQUE, ET DE PRÉVENTION DE LEURS COMPLICATIONS
  申请人：VOLANT HOLDINGS GMBH

  公开号：WO2017203367A2

  公开（公告）日：2017-11-30

  The present invention is directed to a System characterization of NASH that combines Modeling and Biomarkers, enabling pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of Non Alcoholic Fatty Liver Disease (NAFLD) and Hon Alcoholic Steatohepatitis (NASH). Said conditions are Liver related complications among the array of manifestations of.metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, abdominal obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat inhibit or reduce the likelihood of NASH and NAFLD complications in patients with hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, metabolic syndrome complications including cardiovascular diseases, neurodegenerative diseases and premature ageing, among other disease states or conditions.